$11.27
+0.66 (+6.22%)
Open$10.53
Previous Close$10.61
Day High$11.76
Day Low$10.53
52W High$23.47
52W Low$11.96
Volume—
Avg Volume717.0K
Market Cap64.94M
P/E Ratio57.62
EPS$0.31
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+112.4% upside
Current
$11.27
$11.27
Target
$23.94
$23.94
$16.43
$23.94 avg
$27.23
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.74M | 7.84M | 7.34M |
| Net Income | -2,031,310 | -1,359,886 | -1,470,733 |
| Profit Margin | -23.2% | -17.3% | -20.0% |
| EBITDA | -2,389,064 | -2,398,436 | -1,921,173 |
| Free Cash Flow | -1,186,852 | -1,098,506 | -895,782 |
| Rev Growth | +14.6% | -0.2% | +5.0% |
| Debt/Equity | 0.28 | 0.25 | 0.24 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |